Core Viewpoint - The recent financial report of MediTech (603990) shows a significant decline in revenue but a notable increase in net profit, indicating improved profitability despite lower sales [1][4]. Financial Performance Summary - Total revenue for the first half of 2025 was 135 million yuan, a decrease of 47.24% year-on-year [1]. - Net profit attributable to shareholders was 28.33 million yuan, an increase of 137.11% year-on-year [1]. - Gross margin improved significantly to 63.69%, up 650.55% year-on-year, while net margin reached 21.99%, up 174.76% year-on-year [1]. - The total of selling, administrative, and financial expenses was 65.77 million yuan, accounting for 48.65% of revenue, down 16.3% year-on-year [1]. - Earnings per share increased to 0.09 yuan, a rise of 136.0% year-on-year [1]. Changes in Financial Items - Cash and cash equivalents decreased by 11.06% to 265 million yuan, primarily due to the completion of the sale of the photovoltaic business [3][5]. - Accounts receivable decreased by 10.41% to 191 million yuan [1]. - Interest-bearing debt decreased by 72.27% to 284 million yuan, reflecting improved cash flow after the divestiture of the photovoltaic business [1][5]. - The company reported a significant increase in investment income by 9646.46%, attributed to gains from the sale of the photovoltaic business [5]. Strategic Focus and Future Outlook - Following the divestiture of the photovoltaic business, the company is focusing on its core medical business, aiming to enhance operational stability and risk resilience [7]. - The company plans to develop its medical information technology business, emphasizing smart surgery, critical care, and regional medical collaboration [7]. - Analysts expect the company to achieve a net profit of 61 million yuan for the full year of 2025, with an average earnings per share forecast of 0.20 yuan [4].

Group 1 - The company completed a significant asset sale, divesting its solar business subsidiary, effectively optimizing its asset structure and focusing on medical information technology and services [6] - The company reported no profit distribution or capital reserve conversion during the reporting period [4] - The board of directors and supervisory board members confirmed the authenticity and completeness of the semi-annual report [1][2] Group 2 - The company raised a total of RMB 727.60 million through a non-public offering of shares, with a net amount of RMB 706.64 million after deducting issuance costs [7] - As of June 30, 2025, the company had utilized RMB 485.97 million of the raised funds, with specific projects receiving allocations [8] - The company has established a special account for managing the raised funds, ensuring compliance with regulatory requirements [9] Group 3 - The company has temporarily used idle raised funds to supplement working capital, with a balance of RMB 57.47 million remaining as of June 30, 2025 [15] - The company has also engaged in cash management of idle funds, with a total of RMB 35 million utilized for this purpose [16] - There were no instances of using excess raised funds for permanent working capital or loan repayment during the reporting period [17][18] Group 4 - The company has approved the conclusion of the "Regional Critical Illness Collaborative Rescue System Platform Construction Project," reallocating surplus funds for new projects and permanent working capital [19] - The company has adhered to regulations regarding the management and disclosure of raised funds, with no violations reported [22] Group 5 - The company announced the termination of its third employee stock ownership plan due to unfulfilled unlocking conditions, planning to repurchase 1,037,300 shares at a price of RMB 5.21 per share [26][28] - The board of directors approved the repurchase plan, ensuring it aligns with regulatory requirements and does not adversely affect the company's financial status [30][31]

Fundraising Overview - The company has completed a non-public offering of 19,863,488 shares at a price of RMB 36.63 per share, raising a total of RMB 727.60 million, with a net amount of RMB 706.64 million after deducting issuance costs [1] - The company plans to use surplus funds of RMB 192.37 million from the completed project "Regional Emergency and Critical Care Collaborative Treatment System Platform" for new projects and to supplement working capital [2][3] Project Funding Details - The "Regional Emergency and Critical Care Collaborative Treatment System Platform" project utilized RMB 175.04 million of the raised funds, while the new project based on AI technology will receive RMB 129.85 million, and RMB 62.52 million will be used for working capital [2][3] - As of May 31, 2025, the total amount of funds raised and utilized for the projects is detailed in a table format, showing specific amounts for each project [3] Account Management - The company has closed certain fundraising special accounts and transferred the remaining funds to new project accounts, following the completion of the relevant projects [3][4] - New fundraising special accounts have been established with banks, and three-party and four-party supervision agreements have been signed to ensure proper management and usage of the funds [5][6] Regulatory Compliance - The agreements stipulate that the funds in the special accounts are to be used solely for designated projects and cannot be withdrawn as cash or used for other purposes [7][14] - The company and its partners are required to comply with various laws and regulations, including anti-bribery and anti-money laundering provisions [10][12][20] Monitoring and Reporting - The underwriting institution is responsible for ongoing supervision of the fund usage, with provisions for regular audits and reporting to ensure compliance with the agreements [8][21] - Monthly account statements will be provided to the company, and any significant withdrawals must be reported to the underwriting institution [16][22] Conclusion - The company is taking steps to ensure effective management of the raised funds, compliance with regulatory requirements, and protection of investor interests through structured agreements and oversight mechanisms [19][23]

Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., has received approval for its non-public issuance of A-shares and is utilizing its own funds to pay for part of the fundraising investment projects, subsequently replacing these with the raised funds in an equal amount [1][2][9] Fundraising Overview - The company issued 19,863,488 shares at a price of 36.63 yuan per share, raising a total of approximately 727.6 million yuan, with a net amount of about 706.6 million yuan after deducting issuance costs [2][3] Fund Utilization - As of May 31, 2025, the company has allocated funds to two main projects: the Regional Emergency and Critical Care Collaborative Rescue System Platform and the Product Service Upgrade Project based on AI technology, with a total intended investment of approximately 733.5 million yuan and 498.4 million yuan already utilized [3][4] Reasons for Using Own Funds - The company faced challenges in directly using raised funds for certain operational expenses such as salaries, social security, and office costs, which necessitated the use of its own funds initially [5][6] Replacement Process - The company plans to replace the amounts paid with raised funds through a structured process, ensuring compliance with regulations and maintaining efficient fund management [6][7] Impact on Company - The use of self-funds for project expenses followed by replacement with raised funds is expected to enhance fund utilization efficiency and reduce financial costs, aligning with the interests of the company and its shareholders [5][9] Approval Procedures - The company’s board and supervisory committee have approved the use of self-funds for project expenses and the subsequent replacement with raised funds, fulfilling necessary procedural requirements [8][9]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-040 苏州麦迪斯顿医疗科技股份有限公司 苏州麦迪斯顿医疗科技股份有限公司（以下简称"麦迪科技"）于 2025 年 6 月 13 日召开了第四届董事会第三十二次会议、第四届监事会第十六次会议，审 议通过了《关于使用自有资金支付募投项目部分款项并以募集资金等额置换的议 案》，同意公司及子公司苏州优麦机器人有限责任公司（以下简称"苏州优麦"）、 苏州麦迪斯顿医疗管理集团有限公司（以下简称"麦迪医疗"）在募集资金项目 实施期间使用自有资金支付募投项目部分款项并以募集资金进行等额置换。现将 相关事项公告如下： 一、 募集资金基本情况 关于使用自有资金支付募投项目部分款项并以募集资金等额置 换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经中国证券监督管理委员会《关于核准苏州麦迪斯顿医疗科技股份有限公司 非公开发行股票的批复》 （证监许可20202137 号）核准，麦迪科技采用非公开 发行方式发行人民币普通股（A 股）股票，每股面值为人民币 1.00 元，发行数 ...